Today, the CMO of Acelrx (ACRX), Pamela Palmer, bought shares of ACRX for $49.12K.
Following this transaction Pamela Palmer’s holding in the company was increased by 3.51% to a total of $1.44 million. In addition to Pamela Palmer, 2 other ACRX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Acelrx has an average volume of 2.89M.
Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $8.67, reflecting a 184.3% upside. Six different firms, including B.Riley FBR and Cantor Fitzgerald, currently also have a Buy rating on the stock.
The insider sentiment on Acelrx has been positive according to 17 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of acute pain. Its products include DSUVIA and ZALVISO. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
Read More on ACRX:
